Research Article
Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal
Table 2
Clinical and laboratory profile, N(%).
| | Parameters | N(%) or mean ± SD |
| | Enthesitis | 42 (45.2) |
| | Red eye | 34 (37.2) |
| | IBD | 2 (2.3) |
| | Psoriasis | 2 (2.3) |
| | Fatigue | 65 (70.3) |
| | ESR | 41.45 ± 26.51 |
| | CRP | 61.71 ± 44.41 |
| | HLA B27 | 84 (90.9) |
| | Fatigue VAS | 5.30 ± 3.24 |
| | Spinal pain VAS | 6.47 ± 3.01 |
| | Arthritis VAS | 4.44 ± 3.86 |
| | Enthesitis VAS | 2.73 ± 3.79 |
| | MS intensity | 4.18 ± 3.41 |
| | MS duration | 3.06 ± 3.88 |
| | ASDAS CRP | 4.46 ± 1.28 |
| | ASDAS CRP | | | Moderate | 5 (5.1) | | High | 19 (20.5) | | Very high | 68 (74.4) |
|
|
